Status:
COMPLETED
Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed
Lead Sponsor:
AstraZeneca
Conditions:
Erosive Esophagitis
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
A study to look at the rates of remission (non re-appearance of erosive esomeprazole) when treated with esomeprazole or lansoprazole; in patients in with erosive esomeprazole (EE) that is in remission...
Eligibility Criteria
Inclusion
- Episodes of heartburn (described as a burning feeling rising from the stomach or lower part of the chest up towards the neck) for 2 days or more during the last 7 days prior to baseline
- Confirmed diagnosis of Erosive Esophagus, patients must undergo an endoscopy before entering the study.
Exclusion
- Any signs of gastrointestinal bleeding at the time of the starting the study.
- Any previous gastric or esophageal surgery.
- Various gastrointestinal diseases as listed in the protocol.
Key Trial Info
Start Date :
December 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2004
Estimated Enrollment :
750 Patients enrolled
Trial Details
Trial ID
NCT00644735
Start Date
December 1 2002
End Date
January 1 2004
Last Update
March 26 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.